Myocarditis after COVID vaccination is rare but higher in younger males Myocarditis Coronavirus Disease COVID CMAJ UBC CDCofBC
Study: Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study. Image Credit: Lightspring / Shutterstock
Evidence from case reports and case series suggests higher rates of myocarditis among young adults after the mRNA-1273 compared with the BNT162b2 vaccine. Unfortunately, there is a shortage of data concerning the rate of myocarditis after the third vaccine, which is crucial for future booster strategies against COVID-19.
The BC Provincial Immunization Registry is a surveillance platform that compiles population health administrative data, including COVID-19-related laboratory tests, vaccinations, case surveillance, and hospital and intensive care unit [ICU] admissions. It also maintains a record of emergency department visits, physician billings, pharmaceutical dispensations, laboratory tests, chronic diseases, and deaths dating back to 2008.
Study findings The observed rates of myocarditis-related hospital admissions or ED visits after SARS-CoV-2 mRNA vaccination were higher than expected rates. In addition, the researchers noted the highest rates of myocarditis after the second vaccination among males aged 18 to 29 years . Though overall rates of myocarditis per 100000 doses were very low for both mRNA vaccines, the rates were about four-fold higher with the mRNA-1273 vaccine than the BNT162b2 vaccine.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
The negative impact of COVID-19 on working memory revealed using a rapid online quizAlthough coronavirus disease 2019 (COVID-19) affects the respiratory system, it can also have neurological consequences leading to cognitive deficits such as memory problems. The aim of our study was to assess the impact of COVID-19 on working memory function. We developed and implemented an online anonymous survey with a working memory quiz incorporating aspects of gamification to engage participants. 5428 participants successfully completed the survey and memory quiz between 8th December 2020 and 5th July 2021 (68.6% non-COVID-19 and 31.4% COVID-19). Most participants (93.3%) completed the survey and memory quiz relatively rapidly (mean time of 8.84 minutes). Categorical regression was used to assess the contribution of COVID status, age, time post-COVID (number of months elapsed since having had COVID), symptoms, ongoing symptoms and gender, followed by non-parametric statistics. A principal component analysis explored the relationship between subjective ratings and objective memory scores. The objective memory scores were significantly correlated with participants’ own assessment of their cognitive function. The factors significantly affecting memory scores were COVID status, age, time post-COVID and ongoing symptoms. Our main finding was a significant reduction in memory scores in all COVID groups (self-reported, positive-tested and hospitalized) compared to the non-COVID group. Memory scores for all COVID groups combined were significantly reduced compared to the non-COVID group in every age category 25 years and over, but not for the youngest age category (18–24 years old). We found that memory scores gradually increased over a period of 17 months post-COVID-19. However, those with ongoing COVID-19 symptoms continued to show a reduction in memory scores. Our findings demonstrate that COVID-19 negatively impacts working memory function, but only in adults aged 25 years and over. Moreover, our results suggest that working memory deficits with COVID-19 can recov
Læs mere »
CoviRx: A User-Friendly Interface for Systematic Down-Selection of Repurposed Drug Candidates for COVID-19Although various vaccines are now commercially available, they have not been able to stop the spread of COVID-19 infection completely. An excellent strategy to get safe, effective, and affordable COVID-19 treatments quickly is to repurpose drugs that are already approved for other diseases. The process of developing an accurate and standardized drug repurposing dataset requires considerable resources and expertise due to numerous commercially available drugs that could be potentially used to address the SARS-CoV-2 infection. To address this bottleneck, we created the CoviRx.org platform. CoviRx is a user-friendly interface that allows analysis and filtering of large quantities of data, which is onerous to curate manually for COVID-19 drug repurposing. Through CoviRx, the curated data have been made open source to help combat the ongoing pandemic and encourage users to submit their findings on the drugs they have evaluated, in a uniform format that can be validated and checked for integrity by authenticated volunteers. This article discusses the various features of CoviRx, its design principles, and how its functionality is independent of the data it displays. Thus, in the future, this platform can be extended to include any other disease beyond COVID-19.
Læs mere »
Lockdown frustration grows in China's COVID epicentre despite a surge in casesFood supplies and other deliveries are flung over hastily built barriers, while visitors must call out to friends stuck behind the wall which separates parts of Guangzhou.
Læs mere »
Additional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patientsAdditional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patients Antibody Blood BloodCancer Cancer Coronavirus Disease COVID Vaccine NatureComms imperialcollege
Læs mere »